Indication: Neuroblastoma
A Pilot Study of Dinutuximab in Combination with Irinotecan and Temozolomide in the PostConsolidation Setting for High-Risk Neuroblastoma
Sub-indication: Neuroblastoma
Study Type: Drug Study
Principal Investigator: Ashok Raj, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Sponsor: COG
